Article metrics

Original research
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

 

Online download statistics by month:

Online download statistics by month: December 2022 to June 2024

AbstractFullPdf
Dec 2022491496176
Jan 2023785789303
Feb 2023585589174
Mar 2023506507173
Apr 2023405406164
May 2023411412173
Jun 2023421424199
Jul 2023369369176
Aug 2023398399166
Sep 2023393396154
Oct 2023595597159
Nov 2023660661177
Dec 2023495495223
Jan 2024406408234
Feb 2024356335781233
Mar 202419191956892
Apr 202421452165743
May 202416401652630
Jun 202411341151424
Total17321174506573